Global Infant and Baby Cold Medicine Market Research Report 2022

Due to the COVID-19 pandemic, the global Infant and Baby Cold Medicine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Infant and Baby Cold Medicine market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Infant and Baby Cold Medicine landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Oral Medication accounting for % of the Infant and Baby Cold Medicine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Online Sales segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Infant and Baby Cold Medicine include Hyland's Inc, Perrigo, Taro Pharmaceuticals USA, Inc. and Intas Pharmaceuticals Ltd, etc. In terms of revenue, the global 3 largest players have a % market share of Infant and Baby Cold Medicine in 2021.
This report focuses on Infant and Baby Cold Medicine volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Infant and Baby Cold Medicine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Infant and Baby Cold Medicine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Distribution Channel. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Oral Medication
Rectal Suppositories
Segment by Distribution Channel
Online Sales
Drugstore Sales

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Hyland's Inc
Perrigo
Taro Pharmaceuticals USA, Inc.
Intas Pharmaceuticals Ltd